0001209191-17-064491.txt : 20171207
0001209191-17-064491.hdr.sgml : 20171207
20171207171011
ACCESSION NUMBER: 0001209191-17-064491
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171205
FILED AS OF DATE: 20171207
DATE AS OF CHANGE: 20171207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thorp Clay
CENTRAL INDEX KEY: 0001592380
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37783
FILM NUMBER: 171245450
MAIL ADDRESS:
STREET 1: C/O HATTERAS VENTURE PARTNERS III, LP
STREET 2: 280 S. MANGUM ST., SUITE 350
CITY: DURHAM
STATE: NC
ZIP: 27701
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clearside Biomedical, Inc.
CENTRAL INDEX KEY: 0001539029
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452437375
STATE OF INCORPORATION: GA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30005
BUSINESS PHONE: 678-270-3631
MAIL ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30005
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-12-05
0
0001539029
Clearside Biomedical, Inc.
CLSD
0001592380
Thorp Clay
C/O CLEARSIDE BIOMEDICAL, INC.
900 NORTH POINT PARKWAY, SUITE 200
ALPHARETTA
GA
30005
1
0
1
0
Common Stock
2017-12-05
4
S
0
15000
6.37
D
3786394
I
See Footnotes
Common Stock
2017-12-06
4
S
0
15000
6.09
D
3771394
I
See Footnotes
Common Stock
2017-12-07
4
S
0
5000
6.13
D
3766394
I
See Footnotes
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017.
Consists of (i) 13,751 shares sold by Hatteras Venture Partners III, LP ("HVP III") and (ii) 1,249 shares sold by Hatteras Venture Affiliates III, LP ("HVA III").
This transaction was executed in multiple trades at prices ranging from $6.155 to $6.85, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP. HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Partners IV, LP and Hatteras NC Fund, LP.
The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
Consists of (i) 13,751 shares sold by HVP III and (ii) 1,249 shares sold by HVA III.
This transaction was executed in multiple trades at prices ranging from $5.93 to $6.26, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Consists of (i) 4,584 shares sold by HVP III and (ii) 416 shares sold by HVA III.
This transaction was executed in multiple trades at prices ranging from $5.85 to $6.35, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
/s/ Brian F. Leaf, Attorney-in-Fact for Clay Thorp
2017-12-07